CureVac has announced that the first participants in a Phase 3 clinical trial of the CVnCoV vaccine against COVID-19 will be vaccinated on December 22, 2020. The goal of the study is to evaluate the safety and immunogenicity of CVnCoV administered in a two-dose, 12 mcg regimen.